Wire · opportunities
Replimune to ride wave of physician support to launch advanced melanoma therapy
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 29 August 2026 · Fusion42 review
Replimune received FDA approval for Tudriqev to treat advanced melanoma, gaining a broad label with few restrictions. Analysts expect peak sales of $1.3 billion by 2035 as the therapy targets the PD-1-refractory melanoma market with limited treatment options.
This Wire brief sits within Fusion42's coverage of Biotech, and 4 sources have reported it between 7 Aug 2026 and 10 Aug 2026.
◆ ◆ The Wire takeaway
Your melanoma drug just gained broad US approval, opening direct access to a hard-to-treat market with little competition. Now’s the week to prepare for rapid commercial rollout and engage melanoma specialists who backed Tudriqev.
◆ Coverage
4 sources · first reported 7 Aug 2026 · latest 10 Aug 2026
◆ Related on Wire
◆ Topics